Theodossis Theodossiou's project groupProtonics
Use of ionising and non-ionising radiation as cancer therapeutics
The main aim of the PROTONICs team is the combinatory use of ionising radiation-based therapies like Proton Therapy and/or Neutron Capture Therapy, together with light based therapies, like Photodynamic Therapy (PDT) or Photochemical Internalisation to achieve a breakthrough anticancer strategy.
This multifaceted effort also employs the use of cancer-specific nanoparticles, the use of innovative intracellular light sources for PDT, the interplay between various reactive oxygen species and the use of the cancer cells’ own devices to defeat them.
The team further specialises in mitochondrial bioenergetics, the effect of various assaults (chemical, photochemical or radiative) on the mitochondrial respiration and the consequent interplay between respiratory and glycolytic cell metabolism.
Our niche is the design and exploration of novel high risk – high gain experimental therapeutics, including not previously envisaged or anticipated strategies. Our activities are currently supported by local (Helse Sor Ost) as well as European funding (Future and Emerging Technologies and Euronanomed).
The PROTONICs group team members are (in alphabetical order):
Shahla Bagheri-Fam (postdoctoral scholar in project PCInano sponsored by Euronanomed2 – currently on maternity leave)
Mantas Grigalavicius (postdoctoral scholar in project PROTONIC sponsored by Helse Sor Ost).
Maria Mastrangelopoulou (PhD student in project PROTONIC sponsored by Helse Sor Ost).
Mathilde Menard (postdoctoral scholar in project PCInano sponsored by Euronanomed2)
Sepideh Tajik (praxis intern).
Theodossis A. Theodossiou (team leader, senior researcher in project LUMIBLAST sponsored by FET open Horizon 2020).
If you wish to contact us please write to Theodossis.firstname.lastname@example.org or call at +4791828003.